ClinicalTrials.gg
Sign In
RecruitingNCT06779513VANESSAUpdated Jan 16, 2025

Validation and Assessment of Novel Morphology-Voltage-P-wave Score for Diagnosing Left Ventricular Diastolic Dysfunction in Patients With Hypertension

An observational study in Hypertension, sponsored by Universitas Diponegoro. Recruiting at 1 site in Indonesia. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-01-16.

Sponsored by Universitas Diponegoro · Observational

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.
Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
50
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This study aimed to assess and validate the diagnostic utility of a novel Morphology-Voltage-P-wave Score (MVP Score) in identifying left ventricular diastolic dysfunction among patients with hypertension.

Researchers will collect information of patient with hypertension and underwent transthoracal echocardiography assessment. The data consist of demographic data, clinical presentation, laboratory, and echocardiography result were collected by two investigators. Then, the data was analyzed by using IBM SPSS Statistics v26.

02

Conditions studied

  • Hypertension

Browse trials for

03

In context

Hypertension

6,114 studies on the registry are indexed under Hypertension; 912 are open to participants now.

This study's planned enrollment of 50 is below the median of 350 across 1,163 observational studies indexed under Hypertension.

Browse Hypertension studies →

Lead sponsor

Universitas Diponegoro is the lead sponsor of 23 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patient with essential hypertension who came to out hospital

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Essential hypertension

Exclusion criteria

Exclusion Criteria:

  • Secondary or resistant hypertension
  • \<55%
  • Congenital heart disease
  • Infiltrative cardiomyopathy
  • Coronary artery disease
  • Chronic kidney disease
  • Valvular heart disease
  • Bundle branch block
  • Arrhythmia
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patient with LVDD

    Investigators will assess MVP score by reviewing patient 12-lead ECG. Furthermore, the MVP score will be analyzed with echocardiography result.

    Diagnostic Test: Echocardiohraphy

  • Patient without LVDD

    Investigators will assess MVP score by reviewing patient 12-lead ECG. Furthermore, the MVP score will be analyzed with echocardiography result.

    Diagnostic Test: Echocardiohraphy

Interventions

  • Diagnostic testEchocardiohraphy

    Transthoracal echocardiography for diastolic function assessment

06

What researchers measure

Primary outcomes

  1. Diastolic Dysfunction

    Diastolic Dysfunction found in transthoracal echocardiography assessment

    Time frame: Up to 1 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2024 to primary completion in Dec 2024, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2025
First posted
Jan 16, 2025
StartActual
Jan 1, 2024
Primary completionActual
Dec 31, 2024
CompletionEst.
Mar 15, 2025
Last update
Jan 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06779513
Lead sponsor
Universitas Diponegoro
Responsible party
Sodiqur Rifqi (Principal Investigator; Former of Head of Department of Cardiovascular Medicine Faculty of Medicine Universitas Diponegoro, Universitas Diponegoro) — Principal investigator
First posted
Jan 16, 2025
Start date
Jan 1, 2024
Primary completion
Dec 31, 2024
Completion
Mar 15, 2025 (estimated)
Last update
Jan 16, 2025

Study contacts

Leo Deddy Pradipta
Contact
dancingdeagle@gmail.com
+6281316499074

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Hypertension →

Other studies from this sponsor

Universitas Diponegoro

Start the discussion